BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15529157)

  • 1. Biomanufacturing, from bust to boom...to bubble?
    Thiel KA
    Nat Biotechnol; 2004 Nov; 22(11):1365-72. PubMed ID: 15529157
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in the business of culture.
    Pissarra Pde N
    Nat Biotechnol; 2004 Nov; 22(11):1355-6. PubMed ID: 15529153
    [No Abstract]   [Full Text] [Related]  

  • 3. Biotechnology partnerships--medicine for an ailing industry?
    DeLamarter J
    Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
    [No Abstract]   [Full Text] [Related]  

  • 4. The quiet revolution.
    Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
    [No Abstract]   [Full Text] [Related]  

  • 5. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 6. The quiet revolution: outsourcing in pharma.
    Crossley R
    Drug Discov Today; 2004 Aug; 9(16):694. PubMed ID: 15341780
    [No Abstract]   [Full Text] [Related]  

  • 7. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses.
    Mahinka SP; Sanzo KM
    Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000
    [No Abstract]   [Full Text] [Related]  

  • 9. Create products by going virtual.
    Hogan J
    Med Device Technol; 2005 Nov; 16(9):38-9. PubMed ID: 16438448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotech drug market steadily expands.
    Lawrence S
    Nat Biotechnol; 2005 Dec; 23(12):1466. PubMed ID: 16333279
    [No Abstract]   [Full Text] [Related]  

  • 11. Bugs or drugs, tortoises or hares?
    Jacobs T
    Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
    [No Abstract]   [Full Text] [Related]  

  • 12. The promise of the East: India and China as R&D options.
    Goodall S; Janssens B; Wagner K; Wong J; Woods W; Yeh M
    Nat Biotechnol; 2006 Sep; 24(9):1061-4. PubMed ID: 17061321
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant protein therapeutics--success rates, market trends and values to 2010.
    Pavlou AK; Reichert JM
    Nat Biotechnol; 2004 Dec; 22(12):1513-9. PubMed ID: 15583654
    [No Abstract]   [Full Text] [Related]  

  • 14. Can China bring its own pipeline to the market?
    Louët S
    Nat Biotechnol; 2004 Dec; 22(12):1497-9. PubMed ID: 15583646
    [No Abstract]   [Full Text] [Related]  

  • 15. Rediscovering plant-based drugs.
    Littleton J; Falcone D; Davies HM
    Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
    [No Abstract]   [Full Text] [Related]  

  • 16. Trading on traditional medicines.
    Basu P
    Nat Biotechnol; 2004 Mar; 22(3):263-5. PubMed ID: 14990941
    [No Abstract]   [Full Text] [Related]  

  • 17. Commercializing nanotechnology.
    Mazzola L
    Nat Biotechnol; 2003 Oct; 21(10):1137-43. PubMed ID: 14520392
    [No Abstract]   [Full Text] [Related]  

  • 18. Deconstructing Myogen's market cap.
    Ransom J
    Nat Biotechnol; 2006 Mar; 24(3):227-8. PubMed ID: 16525363
    [No Abstract]   [Full Text] [Related]  

  • 19. Cambridge: Europe's leading location for biotechnology.
    Walker J
    Drug Discov Today; 2005 Jul; 10(14):956-9. PubMed ID: 16023052
    [No Abstract]   [Full Text] [Related]  

  • 20. Seizures of Canadian drugs rise as Congress, Customs spar.
    Carreyrou J
    Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.